SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001819790-24-000119
Filing Date
2024-11-05
Accepted
2024-11-05 16:06:18
Documents
13
Period of Report
2024-11-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K tars-20241101.htm   iXBRL 8-K 29474
  Complete submission text file 0001819790-24-000119.txt   158660

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20241101.xsd EX-101.SCH 1773
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20241101_lab.xml EX-101.LAB 22530
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20241101_pre.xml EX-101.PRE 13037
15 EXTRACTED XBRL INSTANCE DOCUMENT tars-20241101_htm.xml XML 2929
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 241427457
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)